Fluoxetine-Induced Cortical Adult Neurogenesis

1] Division of Systems Medical Science, Institute for Comprehensive Medical Science, Fujita Health University, Toyoake, Japan [2] Core Research for Evolutional Science and Technology, Japan Science and Technology Agency, Kawaguchi, Japan.
Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology (Impact Factor: 7.05). 01/2013; 38(6). DOI: 10.1038/npp.2013.2
Source: PubMed


Adult neurogenesis in the hippocampal subgranular zone (SGZ) and the anterior subventricular zone (SVZ) is regulated by multiple factors, including neurotransmitters, hormones, stress, aging, voluntary exercise, environmental enrichment, learning, and ischemia. Chronic treatment with selective serotonin reuptake inhibitors (SSRIs) modulates adult neurogenesis in the SGZ, the neuronal area that is hypothesized to mediate the antidepressant effects of these substances. Layer 1 inhibitory neuron progenitor cells (L1-INP cells) were recently identified in the adult cortex, but it remains unclear what factors other than ischemia affect the neurogenesis of L1-INP cells. Here, we show that chronic treatment with an SSRI, fluoxetine (FLX), stimulated the neurogenesis of gamma-aminobutyric acid (GABA)ergic interneurons from L1-INP cells in the cortex of adult mice. Immunofluorescence and genetic analyses revealed that FLX treatment increased the number of L1-INP cells in all examined cortical regions in a dose-dependent manner. Furthermore, enhanced Venus reporter expression driven by the synapsin I promoter demonstrated that GABAergic interneurons were derived from retrovirally labeled L1-INP cells. In order to assess if these new GABAergic interneurons possess physiological function, we examined the their effect on apoptosis surrounding areas following ischemia. Intriguingly, the number of neurons expressing the apoptotic marker, active caspase-3, was significantly lower in adult mice pretreated with FLX. Our findings indicate that FLX stimulates the neurogenesis of cortical GABAergic interneurons, which might have, at least, some functions, including a suppressive effect on apoptosis induced by ischemia.Neuropsychopharmacology accepted article preview online, 4 January 2013; doi:10.1038/npp.2013.2.

Download full-text


Available from: Koji Ohira, Mar 13, 2014
  • Source
    • "This is of particular importance as even sub-threshold depressive symptoms negatively impact cognitive functions in middle-aged and old subjects (Brevik et al., 2013). Both selective serotonin reuptake inhibitors (SSRIs) and vortioxetine (1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine) are antidepressants that may improve cognitive function (Biringer et al., 2009; Egashira et al., 2006; ElBeltagy et al., 2010; Mork et al., 2013; Wallace et al., 2014) and increase stem cell proliferation in young adult rodents (Guilloux et al., 2013; Ohira et al., 2013), but their effects in older animals have not been well studied. In addition, SSRIs and vortioxetine have different mechanisms of action. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Cognitive decline occurs during healthy aging, even in middle-aged subjects, via mechanisms that could include reduced stem cell proliferation, changed growth factor expression and/or reduced expression of synaptic plasticity genes. Although antidepressants alter these mechanisms in young rodents, their effects in older animals are unclear. In middle-aged mice, we examined the effects of a selective serotonin reuptake inhibitor (fluoxetine) and a multimodal antidepressant (vortioxetine) on cognitive and affective behaviors, brain stem cell proliferation, growth factor and gene expression. Twelve-month-old female C57BL/6 mice exhibited impaired visuospatial memory in the novel object placement (location) task associated with reduced expression of several plasticity-related genes. Chronic treatment with vortioxetine, but not fluoxetine, improved visuospatial memory and reduced depression-like behavior in the forced swim test in middle-aged mice. Vortioxetine, but not fluoxetine, increased hippocampal expression of several neuroplasticity-related genes in middle-aged mice (e.g., Nfkb1, Fos, Fmr1, Camk2a, Arc, Shank1, Nlgn2, and Rab3a). Neither drug reversed the age-associated decrease in stem cell proliferation. Hippocampal growth factor levels were not consistent with behavioral outcomes. Thus, a change in the expression of multiple genes involved in neuronal plasticity by antidepressant treatment was associated with improved cognitive function and a reduction in depression-like behavior in middle-aged mice. Copyright © 2015. Published by Elsevier Inc.
    Full-text · Article · Aug 2015 · Pharmacology Biochemistry and Behavior
  • Source
    • "Effective antidepressant treatment might have a neurobiological impact on depressive disorder by reducing structural shrinkage processes in hippocampus and prefrontal cortex, based on a putative neuroprotective or neuromodulatory effect [140] [141]. In this perspective, antidepressants SSRIs have caused an increase of volume in cingulate subdivisions and precuneus in healthy controls under short administration, confirming a structural remodeling, independent of depressive illness, by serotonergic neurotransmission [142]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Depressive disorder is a very frequent and heterogeneous syndrome. Structural imaging techniques offer a useful tool in the comprehension of neurobiological alterations that concern depressive disorder. Altered brain structures in depressive disorder have been particularly located in the prefrontal cortex (medial prefrontal cortex and orbitofrontal cortex, OFC) and medial temporal cortex areas (hippocampus). These brain areas belong to a structural and functional network related to cognitive and emotional processes putatively implicated in depressive symptoms. These volumetric alterations may also represent biological predictors of response to pharmacological treatment. In this context, major findings of magnetic resonance (MR) imaging, in relation to treatment response in depressive disorder, will here be presented and discussed.
    Full-text · Article · Jul 2015 · Current Neuropharmacology
  • Source
    • "According to Karson et al. (2013), inhibition of TNFa could decrease these affective behaviors in a rat CUMS model. In addition, uoxetine, a selective serotonin reuptake inhibitor (SSRI) antidepressant, can signicantly increase neuron survival in hippocampus of the depression model by modulating hippocampal neurogenesis and apoptosis (Liu et al., 2010; Ohira et al., 2013; Rahmani et al., 2013). Furthermore, uoxetine treatment enhanced cell proliferation and mitigated apoptosis in subgranular zone of hippocampus , and reversed anxiety-and depression-like behaviors (Lee et al., 2001; Yoo et al., 2013). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Mood disorders are a severe health burden but molecular mechanisms underlying mood dysfunction remain poorly understood. Here, we show that wild type p53-induced phosphatase 1 (Wip1) negatively responses to the stress-induced negative mood-related behaviors. Specifically, we show that Wip1 protein but not its mRNA level was downregulated in the hippocampus but not neocortex after 4 weeks of chronic unpredictable mild stress (CUMS) in mice. Moreover, the CUMS responsive WIP1 downregulation in the hippocampus was restored by chronic treatment of fluoxetine (i.p. 20 mg/kg) along with the CUMS procedure. In addition, Wip1 knockout mice displayed decreased exploratory behaviors as well as increased anxiety-like and depression-like behaviors in mice without impaired motor activities under non-CUMS condition. Furthermore, the Wip1 deficiency responsive anxiety-like but not depression-like behaviors were further elevated in mice under CUMS. Although limitations like male-alone sampling and multiply behavioral testing exist, the present study suggests a potential protective function of Wip1 in mood stabilization.
    Full-text · Article · Feb 2015 · Neuroscience
Show more